title: [Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission].
abstract: OBJECTIVE
  To evaluate the efficiency of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloblastic leukemia in first remission depending on the regimens of conditioning, the source of a graft, and the characteristics of a donor and a recipient.
  
  
  METHODS
  In 66 treated patients, including from partially HLA-mismatched relatives (n=4), the efficiency of allo-HSCT from related donors (n=26) and unrelated donors (n=40), were compared. According to cytogenetic findings, 7 (11%), 31 (47%), and 10 (15%) patients belonged to low-, intermediate-, and high-risk groups, respectively.
  
  
  RESULTS
  Five-year overall survival (OS) and mortality associated with transplantation were 56 and 22% for allo-HSCT from related donors, 68 and 23% for that from HLA-matched donors, and 71 and 25% for that from partially HLA-mismatched donors, respectively (p=0.8 and p=0.7). The relapse risk after allo-HSCT from unrelated donors was significantly lower than after that from related donors (13 and 35%, respectively; p=0.8). Univariate analysis showed that the OS rates depended on the cytogenetic risk group (OS was 24 and 64% in the high- and intermediate-risk groups, respectively (p=0.027). The relapse risk in chronic graft-versus-host reaction (GVHR) and in grade 3 acute GVHR (p=0.01) was shown to be less than that in grades 1-2 acute GVHR (p=0.06).
  
  
  CONCLUSIONS
  OS rates after allo-HSCT from related and unrelated donors were comparable and unrelated to the source of a graft, the regimen of conditioning, and other characteristics of a donor and a recipient.
authors.forename: S N
authors.initials: SN
authors.lastname: Bondarenko
authors.forename: E V
authors.initials: EV
authors.lastname: Semenova
authors.forename: V N
authors.initials: VN
authors.lastname: Vavilov
authors.forename: N V
authors.initials: NV
authors.lastname: Stancheva
authors.forename: E V
authors.initials: EV
authors.lastname: Morozova
authors.forename: A L
authors.initials: AL
authors.lastname: Alianskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Babenko
authors.forename: N É
authors.initials: NÉ
authors.lastname: Osipova
authors.forename: L S
authors.initials: LS
authors.lastname: Zubarovskaia
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006648:Histocompatibility; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D012074:Remission Induction; D012720:Severity of Illness Index; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D061349:Unrelated Donors; D055815:Young Adult